These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
456 related articles for article (PubMed ID: 28974128)
1. Can pleiotropic effects of eicosapentaenoic acid (EPA) impact residual cardiovascular risk? Nelson JR; True WS; Le V; Mason RP Postgrad Med; 2017 Nov; 129(8):822-827. PubMed ID: 28974128 [TBL] [Abstract][Full Text] [Related]
2. Reducing residual cardiovascular risk in Europe: Therapeutic implications of European medicines agency approval of icosapent ethyl/eicosapentaenoic acid. Chapman MJ; Zamorano JL; Parhofer KG Pharmacol Ther; 2022 Sep; 237():108172. PubMed ID: 35304222 [TBL] [Abstract][Full Text] [Related]
3. Potential benefits of eicosapentaenoic acid on atherosclerotic plaques. Nelson JR; Wani O; May HT; Budoff M Vascul Pharmacol; 2017 Apr; 91():1-9. PubMed ID: 28263852 [TBL] [Abstract][Full Text] [Related]
4. Effect of Vascepa (icosapent ethyl) on progression of coronary atherosclerosis in patients with elevated triglycerides (200-499 mg/dL) on statin therapy: Rationale and design of the EVAPORATE study. Budoff M; Brent Muhlestein J; Le VT; May HT; Roy S; Nelson JR Clin Cardiol; 2018 Jan; 41(1):13-19. PubMed ID: 29365351 [TBL] [Abstract][Full Text] [Related]
5. Biologic plausibility, cellular effects, and molecular mechanisms of eicosapentaenoic acid (EPA) in atherosclerosis. Borow KM; Nelson JR; Mason RP Atherosclerosis; 2015 Sep; 242(1):357-66. PubMed ID: 26253795 [TBL] [Abstract][Full Text] [Related]
6. Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on remnant-like particle cholesterol from the MARINE and ANCHOR studies. Ballantyne CM; Bays HE; Philip S; Doyle RT; Braeckman RA; Stirtan WG; Soni PN; Juliano RA Atherosclerosis; 2016 Oct; 253():81-87. PubMed ID: 27596132 [TBL] [Abstract][Full Text] [Related]
7. Role of Omega-3 Fatty Acids in Cardiovascular Disease: the Debate Continues. Sherratt SCR; Libby P; Budoff MJ; Bhatt DL; Mason RP Curr Atheroscler Rep; 2023 Jan; 25(1):1-17. PubMed ID: 36580204 [TBL] [Abstract][Full Text] [Related]
8. Effects of switching from omega-3-acid ethyl esters to icosapent ethyl in a statin-treated patient with elevated triglycerides. Kedia AW; Lynch E Postgrad Med; 2015; 127(8):869-73. PubMed ID: 26453247 [TBL] [Abstract][Full Text] [Related]
12. Lipid Effects of Icosapent Ethyl in Women with Diabetes Mellitus and Persistent High Triglycerides on Statin Treatment: ANCHOR Trial Subanalysis. Brinton EA; Ballantyne CM; Guyton JR; Philip S; Doyle RT; Juliano RA; Mosca L J Womens Health (Larchmt); 2018 Sep; 27(9):1170-1176. PubMed ID: 29583081 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study). Ballantyne CM; Bays HE; Kastelein JJ; Stein E; Isaacsohn JL; Braeckman RA; Soni PN Am J Cardiol; 2012 Oct; 110(7):984-92. PubMed ID: 22819432 [TBL] [Abstract][Full Text] [Related]
14. Usefulness of Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) in Women to Lower Triglyceride Levels (Results from the MARINE and ANCHOR Trials). Mosca L; Ballantyne CM; Bays HE; Guyton JR; Philip S; Doyle RT; Juliano RA Am J Cardiol; 2017 Feb; 119(3):397-403. PubMed ID: 27939227 [TBL] [Abstract][Full Text] [Related]
16. Icosapent ethyl for reduction of persistent cardiovascular risk: a critical review of major medical society guidelines and statements. Miller M; Tokgozoglu L; Parhofer KG; Handelsman Y; Leiter LA; Landmesser U; Brinton EA; Catapano AL Expert Rev Cardiovasc Ther; 2022 Aug; 20(8):609-625. PubMed ID: 35876118 [TBL] [Abstract][Full Text] [Related]
17. The case for adding eicosapentaenoic acid (icosapent ethyl) to the ABCs of cardiovascular disease prevention. Trivedi K; Le V; Nelson JR Postgrad Med; 2021 Jan; 133(1):28-41. PubMed ID: 32762268 [TBL] [Abstract][Full Text] [Related]
18. Clinical trials of eicosapentaenoic acid (EPA) prescription products for the treatment of hypertriglyceridemia. Doggrell SA Expert Opin Pharmacother; 2019 Jul; 20(10):1221-1225. PubMed ID: 31038369 [No Abstract] [Full Text] [Related]
19. Icosapent ethyl reduces atherogenic markers in high-risk statin-treated patients with stage 3 chronic kidney disease and high triglycerides. Vijayaraghavan K; Szerlip HM; Ballantyne CM; Bays HE; Philip S; Doyle RT; Juliano RA; Granowitz C Postgrad Med; 2019 Aug; 131(6):390-396. PubMed ID: 31306043 [No Abstract] [Full Text] [Related]
20. Icosapent ethyl for the treatment of hypertriglyceridemia. Ballantyne CM; Braeckman RA; Soni PN Expert Opin Pharmacother; 2013 Jul; 14(10):1409-16. PubMed ID: 23701295 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]